A Study of Elranatamab (PF-06863135) in Chinese Participants With Refractory Multiple Myeloma.
Phase 2 Completed
39 enrolled 15 charts
IFM 2005-03
Phase 2 Completed
13 enrolled
PCD
Phase 2 Completed
100 enrolled
Effects of Hyperbaric Oxygen (HBO) on Blood Count Recovery After Autologous Hematopoietic Stem Cell (HSPC) Transplant for Multiple Myeloma
Phase 2 Completed
99 enrolled 12 charts
A Study of Low Dose Lenalidomide and Dexamethasone in Relapsed/Refractory Myeloma in Patients at High Risk for Myelosuppression
Phase 2 Completed
150 enrolled
Prevention of Treatment Induced Neuropathy in Multiple Myeloma
Phase 2 Completed
79 enrolled 10 charts
Nivolumab Combined With Daratumumab With or Without Low-dose Cyclophosphamide
Phase 2 Completed
62 enrolled
Vaccine Therapy in Treating Patients With Multiple Myeloma
Phase 2 Completed
MUKtwelve
Phase 2 Completed
66 enrolled
Busulfan, Cyclophosphamide, & Antithymocyte Globulin Followed by Stem Cell Transplant in Treating Hematologic Cancer
Phase 2 Completed
5 enrolled 10 charts
Stem Cell Translpantation in Multiple Myeloma
Phase 2 Completed
357 enrolled
Lenalidomide and Melphalan in Treating Patients With Previously Untreated Multiple Myeloma
Phase 2 Completed
51 enrolled
High-Dose Melphalan Plus Peripheral Stem Cell Transplantation in Treating Patients With Primary Systemic Amyloidosis
Phase 2 Completed
Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma
Phase 2 Completed
Biological Therapy in Treating Patients With Multiple Myeloma That Has Recurred Following Bone Marrow Transplantation
Phase 2 Completed
22 enrolled
Shorter Course Tacro After NMA, Related Donor PBSCT With High-dose Posttransplant Cy for Hard-to-Engraft Malignancies
Phase 2 Completed
117 enrolled 27 charts
Combination Chemotherapy and Thalidomide in Treating Patients With Stage I, Stage II, or Stage III Multiple Myeloma
Phase 2 Completed
24 enrolled
OPTIMAL
Phase 2 Completed
31 enrolled 13 charts
KyDaR
Phase 2 Completed
41 enrolled
Intervention for Symptom Burden During Maintenance Therapy for Multiple Myeloma
Phase 2 Completed
88 enrolled 6 charts
Bortezomib, Thalidomide, and Dexamethasone After Melphalan and Stem Cell Transplant in Treating Patients With Stage I-III Multiple Myeloma
Phase 2 Completed
45 enrolled 8 charts
T-BiRD
Phase 2 Completed
26 enrolled 16 charts
Donor Stem Cell Transplant in Treating Patients With Previously Treated Lymphoma, Multiple Myeloma, or Chronic Lymphocytic Leukemia
Phase 2 Completed
6 enrolled 16 charts
Id-KLH Vaccine + T Cells in Subjects With Myeloma Undergoing Transplant
Phase 2 Completed
40 enrolled 8 charts
Busulfan, Cyclophosphamide, and Autologous Stem Cell Transplant in Treating Patients With Multiple Myeloma
Phase 2 Completed
71 enrolled 10 charts
High-Dose Gemcitabine, Busulfan and Melphalan With Hematopoietic-Cell Support for Patients With Poor-Risk Myeloma
Phase 2 Completed
75 enrolled 11 charts
Combination Immunotherapy and Autologous Stem Cell Transplantation for Myeloma
Phase 2 Completed
28 enrolled 8 charts
Thalidomide and Prednisone Following Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma
Phase 2 Completed
67 enrolled
Lenalidomide With or Without Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma
Phase 2 Completed
39 enrolled 13 charts
Stem Cell Transplantation and T-Cell Add-Back to Treat Bone Marrow Malignances
Phase 2 Completed
70 enrolled
Chemotherapy, Radiation Therapy, and Umbilical Cord Blood Transplantation in Treating Patients With Hematologic Cancer
Phase 2 Completed
20 enrolled 11 charts
Peripheral Stem Cell Transplantation in Treating Patients With Hematologic Cancer
Phase 2 Completed
42 enrolled
Peripheral Stem Cell Transplantation Plus Combination Chemotherapy in Treating Patients With Multiple Myeloma
Phase 2 Completed
Peripheral Stem Cell Transplantation Plus Combination Chemotherapy in Treating Patients With Multiple Myeloma
Phase 2 Completed
Oblimersen, Thalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma
Phase 2 Completed
Melphalan+Bortezomib as a Conditioning Regimen for Autologous and Allogeneic Stem Cell Transplants in Multiple Myeloma
Phase 2 Completed
124 enrolled 13 charts
Total-Body Irradiation, Fludarabine, and Peripheral Stem Cell Transplantation in Treating Patients With Hematologic Cancer
Phase 2 Completed
Combination Chemo, Peripheral Stem Cell Transplant, Biological Therapy, Pamidronate and Thalidomide for Multiple Myeloma
Phase 2 Completed
77 enrolled 15 charts
Nelfinavir as Bortezomib-sensitizing Drug in Patients With Proteasome Inhibitor-nonresponsive Myeloma
Phase 2 Completed
34 enrolled
TMC (Topotecan, Cyclophosphamide and Melphalan) for Multiple Myeloma
Phase 2 Completed
60 enrolled
Experimental Bone Marrow Transplant Protocol
Phase 2 Completed
14 enrolled
Combination Chemotherapy, Bone Marrow Transplant, and Post Transplant Cyclophosphamide for Hematologic Cancer
Phase 2 Completed
142 enrolled 11 charts
Anakinra With or Without Dexamethasone in Treating Patients With Smoldering or Indolent Multiple Myeloma
Phase 2 Completed
55 enrolled 14 charts
CC-4047 and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma or Amyloidosis
Phase 2 Completed
378 enrolled 13 charts
Rituximab and Cyclophosphamide in Treating Patients With High Risk, Refractory, or Relapsed Multiple Myeloma
Phase 2 Completed
21 enrolled 5 charts
Tandem Transplantation in Multiple Myeloma (MM) Patients With <12 Months of Prior Treatment
Phase 2 Completed
46 enrolled
Sirolimus, Tacrolimus, and Antithymocyte Globulin in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer Who Are Undergoing Donor Stem Cell Transplant
Phase 2 Completed
48 enrolled 12 charts
AMBER
Phase 2 Completed
102 enrolled 13 charts
Study of the Safety and Pharmacokinetics of Carfilzomib in Patients With Relapsed and Refractory Multiple Myeloma and Varying Degrees of Renal Function
Phase 2 Completed
50 enrolled 33 charts
Bortezomib, Doxorubicin Hydrochloride Liposome, and Thalidomide as First-line Therapy in Treating Patients With Previously Untreated Stage I, II, or III Multiple Myeloma
Phase 2 Completed
46 enrolled 8 charts